Target Price | $44.21 |
Price | $39.23 |
Potential |
12.71%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target PTC Therapeutics, Inc. 2025 .
The average PTC Therapeutics, Inc. target price is $44.21.
This is
12.71%
register free of charge
$66.00
68.24%
register free of charge
$26.00
33.72%
register free of charge
|
|
A rating was issued by 16 analysts: 7 Analysts recommend PTC Therapeutics, Inc. to buy, 6 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2025 of
12.71%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 937.82 | 777.18 |
34.20% | 17.13% | |
EBITDA Margin | -12.03% | -11.96% |
72.09% | 0.57% | |
Net Margin | -68.68% | -49.71% |
19.94% | 27.62% |
15 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2024 . The average PTC Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2024. The average PTC Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average PTC Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -8.37 | -5.02 |
7.45% | 40.02% | |
P/E | negative | |
EV/Sales | 3.10 |
15 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the PTC Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
PTC Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.